Prostate cancer: A closer look at the initial results from the REDUCE trial

Nature Reviews Urology

Volumn 7, Issue 10, 2010, Pages 535-537

  Gann, Peter H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; GLEASON SCORE; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; SHORT SURVEY; TREATMENT OUTCOME;

5-ALPHA REDUCTASE INHIBITORS; AZASTEROIDS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77958028406     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.144     Document Type: Short Survey

References (8)

1. Andriole, G. L. et al. effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192-1202 (2010).
2. Thompson, i. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215-224 (2003).
3. Fleshner, n. e., O'sullivan, M. & Fair, w. R. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J. Urol. 158, 505-508 (1997).
4. Cohen, Y. C. et al. Detection bias due to the effect of finasteride on prostate volume: A modeling approach for analysis of the Prostate Cancer Prevention Trial. J. Natl Cancer Inst. 99, 1366-1374 (2007).
5. Pinsky, P., Parnes, H. & Ford L. estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev. Res. 1, 182-186 (2008).
6. Redman, M. W. et al. Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach. Cancer Prev. Res. 1, 174-181 (2008).
7. Choo, R. et al. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer? Prostate 67, 1614-1620 (2007).
8. Kramer, B. S. et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American society of Clinical Oncology/ American Urological Association 2008 Clinical Practice Guideline. J. Clin. Oncol. 27, 1502-1516 (2009).